Auriga Reiterates a 'Buy' on MedAssets (MDAS); Positive Events Continue to Confirm Thesis

Auriga reiterates a 'Buy' on MedAssets (NASDAQ: MDAS) price target of $16.00.

Auriga analyst said, "A confluence of recent positive events in the last four weeks leads us to reiterate our bullish view on MedAssets at current levels. While execution risk continues as the Company overhauls its revenue cycle business, and the burdensome debt load is hard to ignore, we believe MDAS is digging itself out in a methodical fashion. Though the stock is up some 35% in the latest three months, we still envision 20%+ upside to our $16 target. Next week's annual Health Business Summit, which features a track where the CFO and select MDAS customers will meet with a group of investors and analysts, could provide a catalyst for further gains."

For an analyst ratings summary and ratings history on MedAssets click here. For more ratings news on MedAssets click here.

Shares of MedAssets closed at $13.12 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)
• New Street Research Upgrades Micron Technology (MU) to Buy